Novartis | NOVN - Trade Debtors


Novartis reported $9.6B in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
AbbVie USD 12.59B 180M Dec/2025
Alcon AG USD 2.01B 525M Mar/2026
Almirall EUR 175.93M 17.87M Dec/2025
Amgen USD 9.14B 432M Mar/2026
AstraZeneca USD 17.88B 1.17B Mar/2026
Autolus Therapeutics Ltd USD 38.07M 37.71M Mar/2026
Bayer EUR 18.55B 4.36B Mar/2026
Biogen USD 1.79B 76.6M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Eli Lilly USD 21.18B 1.02B Mar/2026
Fresenius EUR 3.78B 299M Dec/2025
Fresenius Medical Care EUR 3.72B 58.09M Mar/2026
Genmab DKK 1.17B 119M Dec/2025
Gilead Sciences USD 4.74B 172M Mar/2026
GlaxoSmithKline GBP 7.94B 178M Mar/2026
GRIFOLS EUR 958M 106M Mar/2026
Hikma Pharmaceutical USD 1.08B 27M Dec/2025
J&J USD 22.54B 1.21B Mar/2026
Lakefront Biotherapeutics EUR 54.03M 145.72M Mar/2026
Lonza CHF 1.78B 55M Dec/2025
Merck EUR 4.81B 373M Mar/2026
Merck USD 11.78B 345M Dec/2025
Novartis USD 9.6B 2.69B Mar/2026
Novartis USD 9.6B 2.69B Mar/2026
Novo Nordisk DKK 106.26B 11.21B Mar/2026
Orion EUR 699.6M 270.4M Mar/2026
Pfizer USD 16.17B 332M Mar/2026
Philips EUR 3.53B 273M Mar/2026
Recordati EUR 764.73M 88.12M Mar/2026
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Roche Holding CHF 11.9B 460M Dec/2025
Sanofi EUR 482M 85M Mar/2026
UCB EUR 1.97B 54M Dec/2025